In April 2026, Intuitive Surgical voluntarily initiated an ongoing Class II worldwide recall of certain da Vinci surgical system components after discovering an E-brake retainer pin issue that could impede emergency braking or cause uncontrolled column motion, with 454 affected units identified by specific serial numbers.
This safety action, alongside growing attention on Intuitive’s AI-enabled da Vinci 5 rollout and competitive pressures in robotic surgery, raises fresh questions about how operational risks and innovation investments may influence the company’s longer-term growth profile.
Against this backdrop, we’ll examine how the recent Class II recall and upcoming earnings report could reshape Intuitive Surgical’s investment narrative.
Capitalize on the AI infrastructure supercycle with our selection of the 52 best ‘picks and shovels’ of the AI gold rush converting record-breaking demand into massive cash flow.
Intuitive Surgical Investment Narrative Recap
To own Intuitive Surgical, you need to believe robotic-assisted procedures and the da Vinci ecosystem can keep deepening their role in surgery, supporting recurring instrument and service revenue. The immediate catalyst is the upcoming earnings report, with markets focused on procedure trends and margins. The recent Class II recall appears limited in scale, but it adds to operational scrutiny at a time when the key near term risk is already rising quality and safety attention across the da Vinci installed base.
Against this backdrop, the Q1 2026 results are an important reference point: Intuitive reported US$2,770.8 million in revenue and US$821.5 million in net income, with net margins above 28%. Those numbers underpin consensus expectations for mid-teens revenue growth into this week’s earnings, even as the stock is down about 31% year to date and recent recalls, including the E brake retainer pin issue, keep risk management firmly in focus.
Yet investors should also be aware that, even before this recall, concerns around product quality controls and regulatory scrutiny were already…
Read the full narrative on Intuitive Surgical (it’s free!)
Intuitive Surgical’s narrative projects $15.3 billion revenue and $4.5 billion earnings by 2029. This requires 13.1% yearly revenue growth and about a $1.5 billion earnings increase from $3.0 billion today.
Uncover how Intuitive Surgical’s forecasts yield a $565.25 fair value, a 45% upside to its current price.
Exploring Other Perspectives 
ISRG 1-Year Stock Price Chart
You are seeing a wide spread of views here, with the most optimistic analysts expecting revenue of about US$16.7 billion and earnings near US$4.9 billion by 2029, even as recalls and regulatory risks could slow da Vinci 5 adoption and change those assumptions.
Explore 11 other fair value estimates on Intuitive Surgical – why the stock might be worth just $412.72!
Form Your Own Verdict
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
A great starting point for your Intuitive Surgical research is our analysis highlighting 4 key rewards that could impact your investment decision.
Our free Intuitive Surgical research report provides a comprehensive fundamental analysis summarized in a single visual – the Snowflake – making it easy to evaluate Intuitive Surgical’s overall financial health at a glance.
Seeking Other Investments?
Early movers are already taking notice. See the stocks they’re targeting before they’ve flown the coop:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ISRG.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com